The abstract is read at the publisher; the summary is JClub's.
In adults with systemic lupus erythematosus and objective neuropsychological dysfunction, 12-week memantine improved RBANS total scores versus placebo (median change +8 vs +5; P = .032).
- Why it matters: Neuropsychological symptoms in SLE are common and disabling and may persist despite immunomodulatory care, leaving a need for targeted cognitive treatments.
- What they did: ClearMEMory was a multisite, randomized, placebo-controlled 12-week trial in 56 adults with SLE; memantine was titrated to 40 mg/d, with RBANS total score change as the primary endpoint.
- The result: A clinically important RBANS increase (≥8) occurred in 66.7% on memantine and 36.0% on placebo (P = .047; number-needed-to-treat = 3.3), supporting objective cognitive benefit.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.